Eli Lilly to acquire Bothell’s Curevo Vaccine for $1.5 billion - The Seattle Times
1 min readAnalysis by AlgoThesis Editorial Desk
Market Memory
What changed after the headline
The original read stays visible beside later evidence. Connections are editorial records, not ticker-only guesses.
Price since this story
Equal-weight basket · first close after publication
Price context does not establish that the story caused the move.
The story
Eli Lilly is acquiring three vaccine developers including Curevo Vaccine for a combined ~$20B as it pushes into infectious disease. The deal signals a strategic pivot beyond GLP-1 dominance, but near-term EPS dilution and insider selling create a nuanced setup rather than a clean breakout.
The two-sided take
The house read
Wrong ifA rapid sell-side consensus upgrade with higher price targets, strong Q2 earnings beat on GLP-1 volumes, or FDA fast-track on a vaccine asset would quickly reverse the short thesis and squeeze LLY higher through its prior highs.
Published read · research, not advice